Abivax SA (ABVX)
Nasdaq: ABVX · Pharmaceutical Preparations · Paris · filing with the SEC since 2022
Income statement, as filed
In thousands of euros (EUR), as filed; per-share figures in euros; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 23, 2026 | Mar 24, 2025 | Apr 5, 2024 | · | · |
| Research and development | 177,761 | 146,532 | 103,176 | 48,295 | 47,781 |
| Sales and marketing | 5,194 | 5,954 | 6,431 | 0 | 0 |
| General and administrative | 67,670 | 32,946 | 22,390 | 7,492 | 5,580 |
| Total operating expenses | 250,626 | 185,433 | 131,997 | 69,419 | 53,361 |
| Operating income | -246,056 | -172,984 | -127,376 | -64,836 | -41,400 |
| Finance costs | 111,743 | 16,991 | 27,875 | 7,022 | 3,561 |
| Finance income | 27,545 | 13,732 | 7,511 | 11,118 | 2,509 |
| Net finance income (costs) | -84,198 | -3,258 | -20,364 | 4,096 | -1,052 |
| Income before income taxes | -330,254 | -176,242 | -147,740 | -60,740 | -42,452 |
| Income tax expense | 5,848 | 0 | 0 | 0 | 0 |
| Net income | -336,102 | -176,242 | -147,740 | -60,740 | -42,452 |
| Earnings per share, basic | -4.83 | -2.80 | -3.43 | -3.18 | -2.75 |
| Earnings per share, diluted | -4.83 | -2.80 | -3.43 | -3.18 | -2.75 |
| Weighted average shares, basic | 69,527,315 | 63,046,350 | 43,066,012 | 19,092,442 | 15,455,991 |
| Weighted average shares, diluted | 69,527,315 | 63,046,350 | 43,066,012 | 19,092,442 | 15,455,991 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
ifrs-full:SalesAndMarketingExpenseGeneral and administrative the cost of running the company itself
ifrs-full:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
ifrs-full:OperatingExpenseOperating income profit from running the business, before interest and tax
ifrs-full:ProfitLossFromOperatingActivitiesFinance costs what its borrowing cost
ifrs-full:FinanceCostsFinance income what its cash and investments earned
ifrs-full:FinanceIncomeNet finance income (costs) interest earned less interest paid, outside the business
ifrs-full:FinanceIncomeCostIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageSharesWeighted average shares, diluted the average count with every share that could be issued
ifrs-full:AdjustedWeightedAverageShares